News | October 18, 2021
WHO to take call on Covaxin's EUL on October 26th
The WHO chief scientist Soumya Swaminathan tweeted on Oct. 17
The WHO chief scientist Soumya Swaminathan tweeted on Oct. 17
Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations
BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
The applicants will only have to get their Good Manufacturing Practices certification validated every five years to retain their licence
Bharat Biotech has been submitting data to the WHO on a rolling basis and submitted additional information at WHO’s request on September 27th 2021
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
The company plans to submit the IND application by the end of 2021
Subscribe To Our Newsletter & Stay Updated
